Interferon alfa-2b human recombinant possesses antiviral, immunomodulatory, antiproliferative properties, suppresses the replication of RNA and DNA-containing viruses. Immunomodulatory properties of interferon alfa-2b, such as an increase in the phagocytic activity of macrophages, an increase in the specific cytotoxicity of lymphocytes to target cells, cause its mediated antibacterial activity.
In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alfa-2b increases, its immunomodulating effect increases, which allows increasing the efficiency of the organism's own immune response to pathogenic microorganisms. When using the drug, the level of secretory immunoglobulins class A increases, the level of immunoglobulin E normalizes, and the endogenous system of interferon alfa-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and regenerating properties. It was found that when Viferon® is used, there are no side effects arising from the parenteral administration of interferon alfa-2b preparations, antibodies that neutralize the antiviral activity of interferon alfa-2b are not formed. The use of the drug Viferon ® as a part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as to reduce the toxic effects of this therapy.
Cocoa butter contains phospholipids, which make it possible not to use synthetic toxic emulsifiers in production, and the presence of polyunsaturated fatty acids facilitates the introduction and dissolution of the drug.
- Acute respiratory viral infections, including influenza, incl. complicated by bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of complex therapy;
Infectious and inflammatory diseases of newborn children, incl. premature, such as meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis), as part of complex therapy;
- chronic viral hepatitis B, C, D in children and adults as part of complex therapy, incl. in combination with the use of plasmapheresis and hemosorption in chronic viral hepatitis of severe activity complicated by cirrhosis of the liver;
- Infectious-inflammatory diseases of the urogenital tract (chlamydia, cytomegalovirus infection, ureaplasmosis, trichomoniasis, gardnerellez, papillomavirus infection, bacterial vaginosis, recurrent vaginal candidiasis, mycoplasmosis) in adults as part of complex therapy;
- primary or recurrent herpetic infection of the skin and mucous membranes, localized form, mild and moderate-to-moderate flow, incl. urogenital form in adults.
|The purpose of the medication||Antivirus|